Kraig Biocraft Laboratories, Inc. announces today that it has filled two key researcher positions.
ANN ARBOR, Mich., July 19, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has filled two key researcher positions. These new hires hit the ground running with nearly 50 years of combined sericulture experience. The new staff members have been integrated into roles at the intersection of R&D and production to strengthen the transition of new technologies from the lab to the field.
The new staff has introduced new egg treatment/hatching protocol systems that could reduce the rearing cycle by up to 40% during scale-up. Once proven, this approach may allow the Company to accelerate the delivery of its four-strain “double hybrid” production system to its 3rd party contract manufacturer, cutting several months from its original timeline.
The new staff also identified and implemented alternative methods for screening the strength and health of our diverse silkworm colony. That work has led to addressing a previously unknown bottleneck in both laboratory and commercial production. We anticipate that over the next 60 days, this will lead to significantly increased throughput in our U.S. facility. Strengthening our team with these two sericulturists has dramatically enhanced the processes and systems for commercializing our spider silk technologies. We anticipate they will continue to add substantial value to our enterprise over the coming months.
“We are very excited to welcome these additional members to the Kraig Labs team,” said COO Jon Rice. “The 50 years of combined expertise and hands-on sericulture knowledge they bring to the team perfectly complements the bio-engineering prowess of our molecular biology team.”
The Company remains laser-focused on the commercial production of its recombinant spider silk technology. The Company has moved to allocate these additional resources and this new staff as part of its commitment to bringing its revolutionary spider silk technology to market. The Company remains on track for the rollout of its double hybrid production system, and these additional team members further strengthen that timeline.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward-Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
